Experienced in Lung Nodules

Dr. Ashley E. Frith

Oncology
Washington University
150 Entrance Way, St Peters Siteman Cancer C, 
St Peters, MO 
Accepting New Patients
Experienced in Lung Nodules
Washington University
150 Entrance Way, St Peters Siteman Cancer C, 
St Peters, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ashley Frith is an Oncologist in St Peters, Missouri. Dr. Frith is rated as an Experienced provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Frith is currently accepting new patients.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Progress West Hospital
Missouri Baptist Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
150 Entrance Way, St Peters Siteman Cancer C, St Peters, MO 63376
Other Locations
WASHINGTON UNIVERSITY
10 Hospital Dr, Saint Peters, MO 63376
WASHINGTON UNIVERSITY
5225 Mid America Plz, Saint Louis, MO 63129
WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110
WASHINGTON UNIVERSITY
5201 Mid America Plz, Saint Louis, MO 63129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cabozantinib, Nivolumab, Abiraterone, Prednisone
Study Phase: Phase 1
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab
Study Phase: Phase 1/Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Procedure
Study Drugs: Palbociclib, Letrozole, Fulvestrant, Goserelin
Study Phase: Phase 2
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Drugs: Dexrazoxane, Doxorubicin
Study Phase: Phase 2
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells
Enrollment Status: Terminated
Publish Date: November 01, 2022
Intervention Type: Drug, Biological
Study Drugs: Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Study Phase: Phase 2
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
View 12 Less Clinical Trials

14 Total Publications

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
Journal: Cancer
Published: March 05, 2025
Similar Doctors
Distinguished in Lung Nodules
Dr. Bhaskara V. Gadi
Hematology Oncology | Hematology | Oncology
Distinguished in Lung Nodules
Dr. Bhaskara V. Gadi
Hematology Oncology | Hematology | Oncology

Mercy Clinic Oncology LLC

1350 Us Hwy 61, 
Festus, MO 
 (42.2 miles away)
636-931-3655
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bhaskara Gadi is a Hematologist Oncology specialist and a Hematologist in Festus, Missouri. Dr. Gadi is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lymphofollicular Hyperplasia, Lymphoid Hyperplasia, Iron Deficiency Anemia, and Lynch Syndrome. Dr. Gadi is currently accepting new patients.

Distinguished in Lung Nodules
Dr. Muhammad A. Mirza
Hematology Oncology | Oncology
Distinguished in Lung Nodules
Dr. Muhammad A. Mirza
Hematology Oncology | Oncology

Mercy Clinic Oncology LLC

901 Patients 1st Dr, 
Washington, MO 
 (28.4 miles away)
636-390-1600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Muhammad Mirza is a Hematologist Oncology specialist and an Oncologist in Washington, Missouri. Dr. Mirza is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Paget Disease of the Breast. Dr. Mirza is currently accepting new patients.

Advanced in Lung Nodules
Dr. Hsiao O. Hu
Hematology Oncology | Hematology | Oncology
Advanced in Lung Nodules
Dr. Hsiao O. Hu
Hematology Oncology | Hematology | Oncology

Mercy Clinic Oncology LLC

615 S New Ballas Rd 5th Floor, 
St Louis, MO 
 (12.5 miles away)
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Hsiao Hu is a Hematologist Oncology specialist and a Hematologist in St Louis, Missouri. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Angiosarcoma. Dr. Hu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Frith's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile